DK3386956T3 - Fumagillolderivater og polymorfer deraf - Google Patents
Fumagillolderivater og polymorfer deraf Download PDFInfo
- Publication number
- DK3386956T3 DK3386956T3 DK16816157.8T DK16816157T DK3386956T3 DK 3386956 T3 DK3386956 T3 DK 3386956T3 DK 16816157 T DK16816157 T DK 16816157T DK 3386956 T3 DK3386956 T3 DK 3386956T3
- Authority
- DK
- Denmark
- Prior art keywords
- fumagillold
- polymorphes
- derivatives
- fumagillold derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
- C07C309/26—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562265675P | 2015-12-10 | 2015-12-10 | |
PCT/US2016/065799 WO2017100553A1 (en) | 2015-12-10 | 2016-12-09 | Fumagillol derivatives and polymorphs thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3386956T3 true DK3386956T3 (da) | 2021-10-11 |
Family
ID=57589276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16816157.8T DK3386956T3 (da) | 2015-12-10 | 2016-12-09 | Fumagillolderivater og polymorfer deraf |
Country Status (12)
Country | Link |
---|---|
US (2) | US9969722B2 (da) |
EP (1) | EP3386956B1 (da) |
JP (1) | JP2019501898A (da) |
KR (1) | KR20180093995A (da) |
CN (1) | CN108290853B (da) |
AU (1) | AU2016366306B2 (da) |
CA (1) | CA3005450A1 (da) |
DK (1) | DK3386956T3 (da) |
ES (1) | ES2893749T3 (da) |
HK (1) | HK1258254A1 (da) |
MX (2) | MX2018006904A (da) |
WO (1) | WO2017100553A1 (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107141410B (zh) | 2010-05-25 | 2022-12-09 | 辛德弗雷克斯公司 | 聚合物缀合的MetAP2抑制剂及其应用的治疗方法 |
AU2014250983B2 (en) | 2013-04-10 | 2019-04-11 | Syndevrx, Inc. | MetAP2 inhibitors and methods of treating obesity |
CN108697807B (zh) | 2016-01-11 | 2021-11-26 | 辛德弗雷克斯公司 | 代谢功能障碍引起的肿瘤的治疗 |
AU2019366819A1 (en) | 2018-10-26 | 2021-06-03 | Syndevrx Inc. | Biomarkers of MetAP2 inhibitors and applications thereof |
WO2024040009A2 (en) * | 2022-08-17 | 2024-02-22 | Primetime Life Sciences, Llc | Inhibitors of methionine aminopeptidase-2 and methods of preparation and uses thereof |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
SE8702550D0 (sv) | 1987-06-18 | 1987-06-18 | Anders Grubb | Cysteinproteashemmare |
US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
US4997878A (en) | 1988-12-29 | 1991-03-05 | Exxon Research And Engineering Company | Hydrophobically associating polymers containing dimethyl acrylamide functionality |
US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
GB9320781D0 (en) | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
WO1999011272A1 (en) | 1997-09-02 | 1999-03-11 | Johns Hopkins University School Of Medicine | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
JP2002502814A (ja) | 1997-10-31 | 2002-01-29 | チルドレンズ・メディカル・センター・コーポレイション | 血管化した正常組織の大きさおよび増殖の調節のための方法 |
KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
EA003398B1 (ru) | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
US6464850B1 (en) | 1998-07-31 | 2002-10-15 | Biowhittaker Molecular Applications, Inc. | Method for producing hydrophilic monomers and uses thereof |
WO2000025825A1 (fr) | 1998-10-30 | 2000-05-11 | Daiichi Pharmaceutical Co., Ltd. | Composes dds et procede de dosage de ces composes |
AU7025600A (en) | 1999-09-08 | 2001-04-10 | School Of Pharmacy, University Of London, The | Uniform molecular weight polymers |
US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
US20070161570A1 (en) | 2000-11-01 | 2007-07-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
EP1436286B1 (en) | 2001-09-27 | 2009-08-19 | Equispharm Co., Ltd. | Fumagillol derivatives and preparing method thereof |
US20060099660A1 (en) | 2002-02-15 | 2006-05-11 | Synovo Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
CA2480666C (en) | 2002-04-11 | 2012-03-06 | Children's Medical Center Corporation | Tnp-470 polymer conjugates and use thereof |
US20040001801A1 (en) | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
US20040116348A1 (en) | 2002-09-23 | 2004-06-17 | Ying Chau | Polymer-linker-drug conjugates for targeted drug delivery |
US20040228831A1 (en) | 2003-05-15 | 2004-11-18 | Belinka Benjamin A. | Polymeric conjugates for tissue activated drug delivery |
EP2395112B1 (en) | 2003-12-31 | 2017-02-15 | The Penn State Research Foundation | Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
US20070287680A1 (en) | 2004-05-10 | 2007-12-13 | University Of Utah Research Foundation | Combined Active and Passive Targeting of Biologically Active Agents |
US7214664B2 (en) | 2004-12-03 | 2007-05-08 | The Curators Of The University Of Missouri | Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux |
US20080248030A1 (en) | 2005-02-02 | 2008-10-09 | Children's Medical Center Corporation | Method of Treating Angiogenic Diseases |
US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
WO2006124711A1 (en) | 2005-05-16 | 2006-11-23 | The Board Of Trustees Of The University Of Illinois | Composition and method for providing localized delivery of a therapeutic agent |
JP2010531896A (ja) | 2007-06-26 | 2010-09-30 | チルドレンズ メディカル センター コーポレーション | 治療的投与のためのMetAP−2阻害剤ポリマーソーム |
WO2009036108A1 (en) | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
US8399512B2 (en) | 2007-11-28 | 2013-03-19 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
EP2229387A1 (en) * | 2007-12-04 | 2010-09-22 | Cadila Healthcare Limited | Process for preparing chemically and chirally pure solifenacin base and its salts |
EP2244712B1 (en) * | 2008-01-22 | 2015-08-05 | Thar Pharmaceuticals Inc. | In vivo studies of crystalline forms of meloxicam |
CN102105156B (zh) | 2008-05-22 | 2016-05-25 | 特拉维夫大学拉莫特有限公司 | 连接有治疗活性剂和血管生成靶向部分的聚合物的新型缀合物及其在治疗血管生成相关疾病中的用途 |
DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
TWI373345B (en) | 2009-02-19 | 2012-10-01 | Academia Sinica | Breast cancer-targeting peptides and use thereof |
EP2493497A4 (en) | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | INHIBITION OF NOTCH FOR THE TREATMENT AND PREVENTION OF OBESITY AND METABOLIC SYNDROME |
WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
CN107141410B (zh) | 2010-05-25 | 2022-12-09 | 辛德弗雷克斯公司 | 聚合物缀合的MetAP2抑制剂及其应用的治疗方法 |
US20130137831A1 (en) | 2010-05-25 | 2013-05-30 | John S. Petersen | Optimized drug conjugates |
US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
NZ610569A (en) | 2010-11-09 | 2015-06-26 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
WO2012122264A1 (en) | 2011-03-08 | 2012-09-13 | Zafgen Corporation | Oxaspiro [2.5] octane derivatives and analogs |
MX356755B (es) * | 2012-05-09 | 2018-06-11 | Zafgen Inc | Compuestos de tipo fumagilol y metodos para su elaboración y uso. |
AU2014250983B2 (en) | 2013-04-10 | 2019-04-11 | Syndevrx, Inc. | MetAP2 inhibitors and methods of treating obesity |
CN108697807B (zh) | 2016-01-11 | 2021-11-26 | 辛德弗雷克斯公司 | 代谢功能障碍引起的肿瘤的治疗 |
-
2016
- 2016-12-09 WO PCT/US2016/065799 patent/WO2017100553A1/en active Application Filing
- 2016-12-09 ES ES16816157T patent/ES2893749T3/es active Active
- 2016-12-09 CN CN201680072272.XA patent/CN108290853B/zh active Active
- 2016-12-09 MX MX2018006904A patent/MX2018006904A/es unknown
- 2016-12-09 DK DK16816157.8T patent/DK3386956T3/da active
- 2016-12-09 JP JP2018529646A patent/JP2019501898A/ja active Pending
- 2016-12-09 AU AU2016366306A patent/AU2016366306B2/en active Active
- 2016-12-09 CA CA3005450A patent/CA3005450A1/en active Pending
- 2016-12-09 EP EP16816157.8A patent/EP3386956B1/en active Active
- 2016-12-09 US US15/373,874 patent/US9969722B2/en active Active
- 2016-12-09 KR KR1020187019456A patent/KR20180093995A/ko not_active Application Discontinuation
-
2018
- 2018-04-06 US US15/946,899 patent/US10287277B2/en active Active
- 2018-06-06 MX MX2023002589A patent/MX2023002589A/es unknown
-
2019
- 2019-01-15 HK HK19100618.1A patent/HK1258254A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20180093995A (ko) | 2018-08-22 |
ES2893749T3 (es) | 2022-02-10 |
AU2016366306A1 (en) | 2018-05-31 |
US10287277B2 (en) | 2019-05-14 |
EP3386956B1 (en) | 2021-07-14 |
EP3386956A1 (en) | 2018-10-17 |
CN108290853B (zh) | 2022-05-31 |
US20170166556A1 (en) | 2017-06-15 |
CN108290853A (zh) | 2018-07-17 |
US20180291010A1 (en) | 2018-10-11 |
MX2018006904A (es) | 2018-08-24 |
WO2017100553A1 (en) | 2017-06-15 |
CA3005450A1 (en) | 2017-06-15 |
HK1258254A1 (zh) | 2019-11-08 |
MX2023002589A (es) | 2023-03-22 |
JP2019501898A (ja) | 2019-01-24 |
AU2016366306B2 (en) | 2021-02-25 |
US9969722B2 (en) | 2018-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
DK3354282T3 (da) | Glycan-terapeutiske midler og relaterede fremgangsmåder deraf | |
DK3310371T3 (da) | Glucagon og GLP-1-Co-agonistforbindelser | |
DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
DK3368534T3 (da) | Valbenazin-ditosylat og polymorfer deraf | |
DK3380101T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
DK3212189T3 (da) | Substituerede chromaner og fremgangsmåde til anvendelse deraf | |
DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
DK3319612T3 (da) | Oxysteroler og fremgansmåder til anvendelse derfor | |
DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
DK3236991T3 (da) | Fgf21-derivater og anvendelser deraf | |
DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
MA49905A (fr) | Polyesteramines et polyesterquats | |
DK3256479T3 (da) | 4-substituerede benzoxaborolforbindelser og anvendelser deraf | |
DK3386956T3 (da) | Fumagillolderivater og polymorfer deraf | |
DK3273821T3 (da) | Tilpasseligt smykke |